Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00494507 · ClinicalTrials.gov registry record · Phase 3
Hyper- and Hypokalemic Periodic Paralysis Study
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT00494507 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 71 participants.
The verdict
NCT00494507, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.
Interventions
- DRUG Dichlorphenamide (double-blind)
- DRUG Placebo (double-blind)
- DRUG Dichlorphenamide (open-label)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00494507
The ClinicalTrials.gov registry entry for NCT00494507 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dichlorphenamide (double-blind) is the first listed.
NCT00494507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00494507 about?
NCT00494507 is a clinical study titled "Hyper- and Hypokalemic Periodic Paralysis Study". The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic ...
What is the current status of trial NCT00494507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2007-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00494507?
The interventions under investigation include: Dichlorphenamide (double-blind) (DRUG), Placebo (double-blind) (DRUG), Dichlorphenamide (open-label) (DRUG).
Who is sponsoring clinical trial NCT00494507?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.